Histogen (Histogen) EBIT : $-12.38 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Histogen EBIT?

Histogen's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-3.85 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.38 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Histogen's annualized ROC % for the quarter that ended in Sep. 2023 was -407.99%. Histogen's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -596.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Histogen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 402.47%.

Histogen EBIT Historical Data

The historical data trend for Histogen's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen EBIT Chart

Histogen Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EBIT

-1.07

-18.75

-15.00

-10.64

Histogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial													-3.60	-2.97	-3.47	-2.09	-3.85

Competitive Comparison of Histogen's EBIT

For the Biotechnology subindustry, Histogen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Histogen's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Histogen's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Histogen's EV-to-EBIT falls into.

Histogen EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.38 Mil.

Histogen (OTCPK:HSTO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Histogen's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-14.1 * ( 1 - 0% )	/	( (5.744	+	1.168)	/ 2 )
=	-14.1	/	3.456
=	-407.99 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	13.542	-	0.539	-	( 7.259	-	max(0, 0.969	-	8.274	+	7.259	))
=	5.744

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.817	-	0.542	-	( 4.573	-	max(0, 1.348	-	5.455	+	4.573	))
=	1.168

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Histogen's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-15.416	/	( ( (4.852 + max(0.321, 0))	+	(0 + max(-0.466, 0)) )	/	2 )
=	-15.416	/	( ( 5.173	+	0 )	/	2 )
=	-15.416	/	2.5865
=	-596.02 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.015)	-	(0.539	+	0.019	+	0.136)
=	0.321

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.882)	-	(0.542	+	0.019	+	0.787)
=	-0.466

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Histogen's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-12.384	/	-3.077
	=	402.47 %

Histogen EBIT Related Terms

Thank you for viewing the detailed overview of Histogen's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Histogen (Histogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.histogen.com

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Executives

Joyce Reyes	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Richard W Pascoe	director, officer: See Remarks	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Rochelle Fuhrmann	director	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Moya Daniels	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Susan A. Knudson	officer: See Remarks	9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121
Jonathan Jackson	director, 10 percent owner	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Gail K Naughton	officer: See Remarks	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Hugh Crean	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Stephen Chang	director	12912 CAMINO DEL VALLE, POWAY CA 92064
Brian Satz	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Yizhuo Zhang	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Martin Latterich	officer: See Remarks	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Steven J Mento	director	C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Keith W Marshall	officer: EVP, COO & CFO	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127